Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection

This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia at weeks 4, 8, and 12 in combination with levels of baseline viremia. These data may also help to further in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2011-12, Vol.53 (11), p.1111-1114
Hauptverfasser:	Wiegand, Johannes, Neumann, Konrad, Böhm, Stephan, Weich, Viola, Teuber, Gerlinde, Klinker, Hartwig, Möller, Bernd, Rasenack, Jens, Hinrichsen, Holger, Gerlach, Tilman, Spengler, Ulrich, Buggisch, Peter, Sarrazin, Christoph, Berg, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - administration & dosage Biological and medical sciences Branched DNA signal amplification assay BRIEF REPORTS Chronic hepatitis Drug therapy Genotype Genotype & phenotype Genotypes Hepacivirus - classification Hepacivirus - genetics Hepacivirus - isolation & purification Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Human viral diseases Humans Individualization Infections Infectious diseases Interferon-alpha - administration & dosage Kinetics Medical sciences Polyethylene Glycols - administration & dosage Recombinant Proteins - administration & dosage Recurrence Relapse Ribavirin - administration & dosage Risk Assessment RNA Viral diseases Viral hepatitis Viral Load Viremia Virology Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia at weeks 4, 8, and 12 in combination with levels of baseline viremia. These data may also help to further individualize new protease inhibitor-based triple therapy regimens.
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/cir670